NCT02326974 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA (NCT02326974)

Trial Description
This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2.

The names of the study interventions involved in this study are:

Ado-Trastuzumab Emtansine (T-DM1) (Kadcyla®; Genentech, Inc.)
Pertuzumab (Perjeta®; Genentech, Inc.)

This trial is sponsored by Dana-Farber Cancer InstituteNational Cancer Institute (NCI). [1]

Study Data

  • Condition:
    • HER-2 Positive Breast Cancer
    • Breast Cancer
    • Stage II Breast Cancer
    • Stage III Breast Cancer
  • Interventions:
    • Drugs used in this trial
    • Procedure: Excision of tumor/mastectomy
  • Phase: II
  • Estimated Enrollment: 160
  • Start: December 2014
  • Estimated Completion: April 2022
  • Last verified: July 27, 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 27, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.